Compound ID | 2918
Class: Small molecule antibacterial agent
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Active against Enterococcus faecalis, Salmonella typhimurium, and uropathogenic Escherichia coli |
| Description: | Synthetic compound; approved by FDA as chemotherapeutic drug for treating chronic myelogenous leukaemia; a repurposed drug; does not have an intrinsic antibacterial effect but enhances macrophage clearance of bacterial infection |
| Institute where first reported: | Singapore-MIT Alliance for Research and Technology Centre, Antimicrobial Drug Resistance Interdisciplinary Research Group, 138602 Singapore |
| Year first mentioned: | 2024 |
| Development status: | Experimental |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/5328940 |
| Guide to Pharmacology: | bosutinib |
| Citation: | https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00086 |